Reports
Reports
Sale
The global in-vitro colorectal cancer screening tests market size was valued at USD 920.4 million in 2023, with Europe holding a significant market share. The market is driven by the rising prevalence of colorectal cancer across the region. It is expected to grow at a CAGR of 5.53% during the forecast period of 2024-2032, with the values likely to attain USD 1492.8 million by 2032.
Colorectal cancer is the third most common cancer across the globe. It claims nearly 10% of all cancer cases and is the second leading cause of cancer-related deaths worldwide. According to the World Health Organization, in 2020, more than 1.9 million new cases of colorectal cancer were recorded globally. Europe, Australia, and New Zealand experienced the highest incidence rates, and the mortality rates were highest in Eastern Europe. It is expected that the burden of colorectal cancer will increase to 3.2 million new cases per year (an increase of 63%) by 2040, and 1.6 million deaths per year (an increase of 73%).
Europe in-vitro colorectal cancer screening tests market share is expected to be elevate with increasing strategic moves of market players. Considering the urgency of diagnosing colorectal cancer in its early stages with accuracy, there have been dedicated efforts to develop effective products. On January 9, 2024, a clinical-stage diagnostics company Dxcover Limited, pioneering in multi-omic spectral analysis (MOSA) for the early detection of multiple cancers, announced the initiation of three pivotal clinical trials, measuring the efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal, and lung cancer. Their CREATE2 trial is focused on evaluating the diagnostic accuracy for colorectal cancer and high-risk adenoma in patients who have been going through colonoscopy. With colorectal cancer already difficult to diagnose in early detection screenings, diagnosis at these stages will enable positive patient outcomes.
Europe in-vitro colorectal cancer screening tests market growth is anticipated to be positively impacted by the researchers innovating new testing methods for the detection of precursors of colorectal cancer. For instance, in February 2024, researchers at the Netherlands Cancer Institute, Amsterdam UMC, and Erasmus MC developed a new test, titled multitargetFIT-test (mtFIT). With the existing FIT test, the patient’s stool is analysed for hemoglobin, however mtFIT measures hemoglobin and two additional proteins. mtFIT is targeted to detect cancer precursors more effectively. Notable outcomes have also been registered in a large prospective study, in which mtFIT effectively detected cancer precursors in comparison to the current FIT. Based on the diagnostic test guidelines in Europe, the next step is to produce the mtFIT test on a larger industrial scale. This is because the test can be included in existing FIT-based screening programs, as the screening logistics requirements are similar. To facilitate the availability of the test for CRC screening participants in the Netherlands and other places, a company called CRCbioscreen has also been established.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup | Categories |
Testing Type | Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Flexible Sigmoidoscopy, Others |
Imaging Type | Colonoscopy, Proctoscopy, CT scan, Ultrasound, MRI, PET Scan |
End User | Hospitals, Clinics, Diagnostics Laboratories |
Country | United Kingdom, Germany, France, Italy, Others |
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Testing Type |
|
Breakup by Imaging Type |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Europe In-vitro Colorectal Cancer Screening Tests Market Overview
3.1 Europe In-vitro Colorectal Cancer Screening Tests Market Historical Value (2017-2023)
3.2 Europe In-vitro Colorectal Cancer Screening Tests Market Forecast Value (2024-2032)
4 Europe In-vitro Colorectal Cancer Screening Tests Market Landscape*
4.1 Europe In-vitro Colorectal Cancer Screening Tests: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Europe In-vitro Colorectal Cancer Screening Tests: Product Landscape
4.2.1 Analysis by Test Type
4.2.2 Analysis by Imaging Type
5 Europe In-vitro Colorectal Cancer Screening Tests Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Europe In-vitro Colorectal Cancer Screening Tests Market Segmentation (2017-2032)
6.1 Europe In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
6.1.1 Market Overview
6.1.2 Fecal Occult Blood Tests
6.1.3 Biomarker Tests
6.1.4 CRC DNA Screening Tests
6.1.5 Flexible Sigmoidoscopy
6.1.6 Others
6.2 Europe In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
6.2.1 Market Overview
6.2.2 Colonoscopy
6.2.3 Proctoscopy
6.2.4 CT scan
6.2.5 Ultrasound
6.2.6 MRI
6.2.7 PET Scan
6.3 Europe In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Clinics
6.3.4 Diagnostics Laboratories
6.3.5 Others
6.4 Europe In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
6.4.1 Market Overview
6.4.2 United Kingdom
6.4.3 Germany
6.4.4 France
6.4.5 Italy
6.4.6 Others
7 United Kingdom In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
7.1 United Kingdom In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
7.1.1 Market Overview
7.1.2 Fecal Occult Blood Tests
7.1.3 Biomarker Tests
7.1.4 CRC DNA Screening Tests
7.1.5 Flexible Sigmoidoscopy
7.1.6 Others
7.2 United Kingdom In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
7.2.1 Market Overview
7.2.2 Colonoscopy
7.2.3 Proctoscopy
7.2.4 CT Scan
7.2.5 Ultrasound
7.2.6 MRI
7.2.7 PET Scan
7.3 United Kingdom In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
7.3.1 Market Overview
7.3.2 Hospitals
7.3.3 Clinics
7.3.4 Diagnostics Laboratories
7.3.5 Others
8 Germany In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
8.1 Germany In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
8.1.1 Market Overview
8.1.2 Fecal Occult Blood Tests
8.1.3 Biomarker Tests
8.1.4 CRC DNA Screening Tests
8.1.5 Flexible Sigmoidoscopy
8.1.6 Others
8.2 Germany In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
8.2.1 Market Overview
8.2.2 Colonoscopy
8.2.3 Proctoscopy
8.2.4 CT Scan
8.2.5 Ultrasound
8.2.6 MRI
8.2.7 PET Scan
8.3 Germany In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
8.3.1 Market Overview
8.3.2 Hospitals
8.3.3 Clinics
8.3.4 Diagnostics Laboratories
8.3.5 Others
9 France In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
9.1 France In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
9.1.1 Market Overview
9.1.2 Fecal Occult Blood Tests
9.1.3 Biomarker Tests
9.1.4 CRC DNA Screening Tests
9.1.5 Flexible Sigmoidoscopy
9.1.6 Others
9.2 France In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
9.2.1 Market Overview
9.2.2 Colonoscopy
9.2.3 Proctoscopy
9.2.4 CT Scan
9.2.5 Ultrasound
9.2.6 MRI
9.2.7 PET Scan
9.3 France In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
9.3.1 Market Overview
9.3.2 Hospitals
9.3.3 Clinics
9.3.4 Diagnostics Laboratories
9.3.5 Others
10 Italy In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
10.1 Italy In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
10.1.1 Market Overview
10.1.2 Fecal Occult Blood Tests
10.1.3 Biomarker Tests
10.1.4 CRC DNA Screening Tests
10.1.5 Flexible Sigmoidoscopy
10.1.6 Others
10.2 Italy In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
10.2.1 Market Overview
10.2.2 Colonoscopy
10.2.3 Proctoscopy
10.2.4 CT Scan
10.2.5 Ultrasound
10.2.6 MRI
10.2.7 PET Scan
10.3 Italy In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
10.3.1 Market Overview
10.3.2 Hospitals
10.3.3 Clinics
10.3.4 Diagnostics Laboratories
10.3.5 Others
11 Regulatory Framework
12 Funding and Investment Analysis
12.1 Analysis by Funding Instances
12.2 Analysis by Type of Funding
12.3 Analysis by Funding Amount
12.4 Analysis by Leading Players
12.5 Analysis by Leading Investors
12.6 Analysis by Geography
13 Partnership and Collaborations Analysis
13.1 Analysis by Partnership Instances
13.2 Analysis by Type of Partnership
13.3 Analysis by Leading Players
13.4 Analysis by Geography
14 Supplier Landscape
14.1 Market Share by Top 5 Companies
14.2 Epigenomics AG
14.2.1 Financial Analysis
14.2.2 Product Portfolio
14.2.3 Demographic Reach and Achievements
14.2.4 Mergers and Acquisitions
14.2.5 Certifications
14.3 NOVIGENIX SA
14.3.1 Financial Analysis
14.3.2 Product Portfolio
14.3.3 Demographic Reach and Achievements
14.3.4 Mergers and Acquisitions
14.3.5 Certifications
14.4 Merck KGaA
14.4.1 Financial Analysis
14.4.2 Product Portfolio
14.4.3 Demographic Reach and Achievements
14.4.4 Mergers and Acquisitions
14.4.5 Certifications
14.5 Abbott
14.5.1 Financial Analysis
14.5.2 Product Portfolio
14.5.3 Demographic Reach and Achievements
14.5.4 Mergers and Acquisitions
14.5.5 Certifications
14.6 Siemens Healthineers AG
14.6.1 Financial Analysis
14.6.2 Product Portfolio
14.6.3 Demographic Reach and Achievements
14.6.4 Mergers and Acquisitions
14.6.5 Certifications
14.7 Sysmex Corporation
14.7.1 Financial Analysis
14.7.2 Product Portfolio
14.7.3 Demographic Reach and Achievements
14.7.4 Mergers and Acquisitions
14.7.5 Certifications
14.8 Qiagen NV
14.8.1 Financial Analysis
14.8.2 Product Portfolio
14.8.3 Demographic Reach and Achievements
14.8.4 Mergers and Acquisitions
14.8.5 Certifications
14.9 F. Hoffmann-La Roche Ltd
14.9.1 Financial Analysis
14.9.2 Product Portfolio
14.9.3 Demographic Reach and Achievements
14.9.4 Mergers and Acquisitions
14.9.5 Certifications
14.10 Eiken Chemical Co., Ltd.
14.10.1 Financial Analysis
14.10.2 Product Portfolio
14.10.3 Demographic
14.10.4 Mergers and Acquisitions
14.10.5 Certifications
14.11 Beckman Coulter, Inc.
14.11.1 Financial Analysis
14.11.2 Product Portfolio
14.11.3 Demographic Reach and Achievements
14.11.4 Mergers and Acquisitions
14.11.5 Certifications
15 Europe In-vitro Colorectal Cancer Screening Tests Market – Distribution Model (Additional Insight)
15.1 Overview
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
16 Key Opinion Leaders (KOL) Insights (Additional Insight)
17 Company Competitiveness Analysis (Additional Insight)
17.1 Very Small Companies
17.2 Small Companies
17.3 Mid-Sized Companies
17.4 Large Companies
17.5 Very Large Companies
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The Europe in-vitro colorectal cancer screening tests market is expected to be driven by the increasing research activities in the global market, which is anticipated to grow at a CAGR of 5.53% during the forecast period of 2024-2032, and is likely to reach a market value of USD 1492.8 million by 2032.
Factors aiding the market demand include increasing prevalence of colorectal cancer along with market players understanding the importance of urgent requirements for new and effective screening tests for early detection of cancer.
Major trends influencing the market growth include researchers innovating new testing methods for detecting colorectal cancer precursors. For instance, in February 2024, researchers at the Netherlands Cancer Institute, Amsterdam UMC, and Erasmus MC developed a new test, called multitargetFIT-test (mtFIT).
Based on the testing type, the market is segmented into fecal occult blood tests, biomarker tests, CRC DNA screening tests, and flexible sigmoidoscopy, among others.
By imaging type, the market is divided into colonoscopy, proctoscopy, CT scan, ultrasound, MRI, and PET scan, among others.
End users of the market are hospitals, clinics, and diagnostics laboratories.
The market segmentation by countries includes the United Kingdom, Germany, France, Italy and others.
The key players in the market are Epigenomics AG, NOVIGENIX SA, Merck KGaA, Abbott, Siemens Healthineers AG, Sysmex Corporation, F. Hoffmann-La Roche Ltd, Eiken Chemical Co., Ltd., Beckman Coulter, Inc., and Qiagen NV.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.